Friday, 16 October 2026European Markets

BLEECKER And MERCIALYS Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - bleecker (blee.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
bleecker (blee.pa) €202.00 18.23% 26.04%
mercialys (mery.pa) €10.52 9.28% 5.53%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. bleecker (blee.pa)

18.23% forward dividend yield and 26.04% return on equity

bleecker société anonyme, a property company, operates in the real estate sector in france. the company develops and manages industrial premises, offices, and logistics platforms. as of august 31, 2010, it had 26 properties or property complexes covering a surface area of 208,228 square meters. the company is based in paris, france.

earnings per share

as for profitability, bleecker has a trailing twelve months eps of €28.31.

pe ratio

bleecker has a trailing twelve months price to earnings ratio of 7.14. meaning, the purchaser of the share is investing €7.14 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.04%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, bleecker's stock is considered to be oversold (<=20).

volatility

bleecker's last week, last month's, and last quarter's current intraday variation average was 1.00%, 0.52%, and 4.77%.

bleecker's highest amplitude of average volatility was 1.00% (last week), 4.71% (last month), and 4.77% (last quarter).

moving average

bleecker's value is above its 50-day moving average of €197.24 and higher than its 200-day moving average of €188.93.

more news about bleecker.

2. mercialys (mery.pa)

9.28% forward dividend yield and 5.53% return on equity

mercialys is one of france's leading real estate companies, focused exclusively on shopping centers and high-street retail assets. at june 30, 2020, mercialys had a portfolio of 2,111 leases, representing a rental value of euro 182.3 million on an annualized basis. at june 30, 2020, it owned properties with an estimated value of euro 3.5 billion (including transfer taxes). mercialys has had “siic” real estate investment trust (reit) tax status since november 1, 2005 and has been listed on euronext paris compartment a (ticker: mery) since its initial public offering on october 12, 2005. at june 30, 2020, there were 92,049,169 shares outstanding.

earnings per share

as for profitability, mercialys has a trailing twelve months eps of €0.47.

pe ratio

mercialys has a trailing twelve months price to earnings ratio of 22.38. meaning, the purchaser of the share is investing €22.38 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.53%.

volume

today's last reported volume for mercialys is 44697 which is 82.13% below its average volume of 250189.

volatility

mercialys's last week, last month's, and last quarter's current intraday variation average was a positive 0.24%, a negative 0.06%, and a positive 1.36%.

mercialys's highest amplitude of average volatility was 1.84% (last week), 1.28% (last month), and 1.36% (last quarter).

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 2, 2023, the estimated forward annual dividend rate is 0.96 and the estimated forward annual dividend yield is 9.28%.

more news about mercialys.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com